SANUWAVE Health Announces $3 Million Financing

Rhea-AI Summary

SANUWAVE Health (OTCQB:SNWV) has announced a $3 million private placement financing to enhance its growth initiatives in wound care products. The financing will occur in three tranches of $1 million and aims to strengthen the company’s balance sheet throughout 2021. CEO Kevin Richardson expressed optimism about the new capital allowing the company to advance its product offerings and improve wound care solutions. The company plans to file its third quarter 2020 Form 10-Q/A with the SEC soon, followed by its Annual Report on Form 10-K, with revenue guidance updates expected thereafter.

Positive

• Secured $3 million in private placement financing to bolster growth initiatives.
• Financing structured in three tranches, enhancing financial stability.
• Plans to file important financial reports (10-Q/A and 10-K) soon, indicating commitment to transparency and shareholder communications.

Negative

• Potential risks related to regulatory approval and marketing of products could impact future performance.
• The company may face challenges in managing capital resources.

Capital to Accelerate the Company's Near-Term Growth Initiatives

SUWANEE, GA /ACCESSWIRE / April 28, 2021 / SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products, today announced a $3 million private placement financing with Kingswood Capital Markets acting as placement agent.

Commenting on the capital raise, Kevin Richardson, Chief Executive Officer stated, "We are pleased to have secured this additional capital, enabling us to accelerate near-term growth initiatives for our innovative suite of wound care products. This financing will be paid in three tranches of $1 million each, fortifying our balance sheet as we progress through 2021.

"We continue to realize exciting new capital markets milestones and fully expect to file our third quarter 2020 Form 10-Q/A with the SEC within the next two weeks and the Annual Report on Form 10-K shortly thereafter. We anticipate providing an update on the business and full year revenue guidance following the filing of the 10-K. With these new developments, we can continue to focus on improving wound care through our portfolio of noninvasive and biological-response therapeutics," concluded Richardson.

About SANUWAVE Health

SANUWAVE Health (OTCQB:SNWV) is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac/endovascular conditions. For more information, please visit. www.SANUWAVE.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Investor Relations Contact
Brian M. Prenoveau, CFA
Managing Director
MZ Group - MZ North America
(561) 489-5315
SNWV@mzgroup.us
www.mzgroup.us

SOURCE: SANUWAVE Health, Inc.

View source version on accesswire.com:
https://www.accesswire.com/642712/SANUWAVE-Health-Announces-3-Million-Financing

FAQ

What is the recent financing amount for SANUWAVE Health (SNWV)?

SANUWAVE Health announced a $3 million private placement financing.

How will the $3 million financing be structured for SANUWAVE Health?

The financing will be paid in three tranches of $1 million each.

What future reports will SANUWAVE Health file that could impact investors?

SANUWAVE Health plans to file its third quarter 2020 Form 10-Q/A and Annual Report on Form 10-K.

What challenges could impact SANUWAVE Health's future business performance?

Challenges include risks associated with regulatory approvals and managing capital resources.